A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ApexOnco Front Page
Recent articles
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
BG-75202 features among several projects starting first-in-human trials.
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Blackstone follows Abingworth, but why?
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
